A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies

Simple item page
dc.contributor.authorMcKay, R.
dc.contributor.authorDe Velasco, G.
dc.contributor.authorWerner, L.
dc.contributor.authorBellmunt, J.
dc.contributor.authorHarshman, L.
dc.contributor.authorSweeney, C.
dc.contributor.authorRosenberg, J.
dc.contributor.authorHirsch, M.
dc.contributor.authorSignoretti, S.
dc.contributor.authorVan Allen, E.
dc.contributor.authorWalsh, M.
dc.contributor.authorVaishampayan, U.
dc.contributor.authorMcDermott, D.
dc.contributor.authorChoueiri, T.
dc.date.issued2016
dc.description.abstractAbstract not available
dc.description.statementofresponsibilityRana R. McKay, Guillermo De Velasco, Lillian Werner, Joaquim Bellmunt, Lauren Harshman, Christopher Sweeney, Jonathan E. Rosenberg, Michelle Hirsch, Sabina Signoretti, Eliezer M. Van Allen, Meghara Walsh, Ulka Vaishampayan, David F. McDermott, and Toni K. Choueiri
dc.identifier.citationCancer, 2016; 122(15):2389-2398
dc.identifier.doi10.1002/cncr.30056
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.orcidSweeney, C. [0000-0002-0398-6018]
dc.identifier.urihttp://hdl.handle.net/2440/106367
dc.language.isoen
dc.publisherWiley-Blackwell
dc.rights© 2016 American Cancer Society
dc.source.urihttps://doi.org/10.1002/cncr.30056
dc.subjectBevacizumab; buparlisib; phase 1; phosphatidylinositol-3 kinase (PI3K) inhibitor; renal cell carcinoma
dc.titleA phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications